• Home
  • Products & Services
    • VBS Pharmaceuticals
      • CAR Peptide Technology
      • CAR Peptide Applications
        • Co-administered Therapeutics
        • Pulmonary Hypertension
        • Sepsis
        • Gene Therapy
    • VBS Interventional
      • Interventional Technology
        • Endoarterial Biopsy Catheter
        • Endoarterial Biopsy Procedure
        • Endoarterial Biopsy Sequence
        • Endoarterial Biopsy Sample
        • Single Use Components
        • Endoarterial Biopsy Kit
      • Interventional Applications
        • Pulmonary Arterial Hypertension
        • Peripheral Vascular Disease
        • Lung Transplant Rejection
        • Vasculitis/Collagen Vascular Disease
        • Coronary Artery Disease
        • Critical Care Applications — Acute Lung Injury & Acute Respiratory Distress Syndrome
        • Lung Cancer
    • VBS Molecular Diagnostics
      • Molecular Diagnostics Technology
  • Product Pipeline
  • COVID-19
  • News
  • About VBS
    • Quality
    • VBS Team
    • VBS Board of Directors
  • VBS Scientific Articles
  • Investment
  • Contact

Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.

Oct 11, 2012
by admin
Comments are off
Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant. Goleta, CA., October 11, 2012 – Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to de
Read More

Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium

Oct 10, 2012
by admin
Comments are off
Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium San Diego, CA., October 10, 2012 – Vascular BioSciences announces CEO David Mann will presen
Read More

Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry

Jul 03, 2012
by admin
Comments are off
Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry Goleta, Calif., July 3, 2012 – Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry. Dr. Kahn, an expert in computational chem
Read More

Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension”

Jun 27, 2011
by admin
Comments are off
Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension” Durnham, North Carolina, June 27, 2011 – Vascular BioSciences announces the publication of a scientific articl
Read More

Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Selected by Faculty of 1000

Jun 24, 2011
by admin
Comments are off
Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Selected by Faculty of 1000 Goleta, Calif., June 24, 2011 – A recently published paper from Vascular BioSciences (VBS) in collaboration with Sanford-Burnham Medical Research Institute and the University of
Read More

VBS Pharmaceuticals announces publication of “Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension”

Jun 10, 2011
by admin
Comments are off
VBS Pharmaceuticals announces publication of “Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Goleta, Calif., June 10, 2011 – VBS Pharmaceuticals, in collaboration with the Sanford-Burnham Medical Research Institute, and the University of South Alabama,
Read More

David Mann, CEO of Vascular BioSciences, Presents Opening Remarks at the Southern California Undergraduate Research Conference in Chemistry and Biochemistry (SCURC)

Apr 24, 2011
by admin
Comments are off
David Mann, CEO of Vascular BioSciences, Presents Opening Remarks at the Southern California Undergraduate Research Conference in Chemistry and Biochemistry (SCURC) Santa Barbara, Calif., April 24, 2011 – Opening speaker David Mann presented the following remarks at the SCURC at the U
Read More

Vascular BioSciences to Sponsor 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistry

Apr 23, 2011
by admin
Comments are off
Vascular BioSciences to Sponsor 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistry Santa Barbara, Calif., April 23, 2011 – Vascular BioSciences will be a major sponsor of the 2011 Southern California Undergraduate Research Conference in Chemistry
Read More

Vascular BioSciences, In Collaboration with the University of South Alabama, Awarded Exploration/Development R21 Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Cell-targeted Drug Delivery for the Treatment of Pulmonary Arterial Hypertension (PAH)

Dec 24, 2010
by admin
Comments are off
Vascular BioSciences, In Collaboration with the University of South Alabama, Awarded Exploration/Development R21 Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Cell-targeted Drug Delivery for the Treatment of Pulmonary Arterial Hypertension
Read More

Vascular BioSciences Awarded Qualifying Therapeutic Discovery Project Grant to Develop CAR Peptide as a Therapeutic Adjuvant

Nov 09, 2010
by admin
Comments are off
Vascular BioSciences Awarded Qualifying Therapeutic Discovery Project Grant to Develop CAR Peptide as a Therapeutic Adjuvant San Diego, CA, November 9, 2010 – Vascular BioSciences was awarded a grant in the amount of $181,876 from the U.S. Government’s Qualifying Therapeutic Discovery
Read More
12345
  • Home
  • Products & Services
  • Product Pipeline
  • News
  • About VBS
  • VBS Scientific Articles
  • Investment
  • Contact Info
  • Privacy Policy